{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-040317","form_type":"8-K","ticker":"CELC","cik":"0001603454","company_name":"Celcuity Inc.","filed_at":"2023-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.738255+00:00","generated_at":"2026-06-08T05:13:14.215362+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Celcuity Q3 net loss $18.4M; raises $50M; advances gedatolisib in prostate cancer","bullets":["Q3 net loss $18.4M ($0.83 loss per share) vs $10.9M ($0.75) YoY; non-GAAP adjusted loss $17.3M ($0.78).","Closed $50M private placement equity in October 2023; cash runway extended into mid-2026.","FDA cleared IND for gedatolisib + darolutamide in mCRPC; entered Bayer supply agreement for darolutamide.","VIKTORIA-1 Phase 3 (HR+/HER2- breast cancer) on track: PIK3CA wt data H2 2024, PIK3CA mut data H1 2025.","CELC-G-201 Phase 1b/2 (mCRPC) site activation Q1 2024; initial data expected H1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-040317","json":"https://secwatch.observer/filing/0001493152-23-040317.json","markdown":"https://secwatch.observer/filing/0001493152-23-040317.md","text":"https://secwatch.observer/filing/0001493152-23-040317.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1603454/000149315223040317/0001493152-23-040317-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1603454/000149315223040317/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T05:13:14.215362+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"371ca65f2ca0615999d811226e40d8903a5e77ab","claim":"Celcuity Inc. reported the third quarter ended September 30, 2023 results: net income $18.4 million, EPS $0.83 loss per share.","evidence_excerpt":"Net loss for the third quarter of 2023 was $18.4 million, or $0.83 loss per share, compared to a net loss of $10.9 million, or $0.75 loss per share, for the third quarter of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1603454/000149315223040317/0001493152-23-040317-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Net income","value":"$18.4 million"},{"label":"EPS","value":"$0.83 loss per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}